Last checked at 16 Nov 2017 07:00
16 November 2017
IXICO plc
("IXICO" or the "Company")
IXICO signs its first contract with a new biopharma customer to deploy biosensors in a late stage clinical trial for a psychiatric disorder
Further expansion of IXICO's biopharma customer base and wearable biosensor technology
IXICO plc (AIM: IXI), the digital technologies company serving neuroscience, today announces that it has signed a new contract with another leading biopharmaceutical company to support the use of wrist worn activity sensors ('wearable biosensors') in a late stage trial for a psychiatric disorder.
This contract with a new biopharma customer has a value c. £0.75m over a two year term, commencing in November 2017. IXICO will utilise its biosensor capabilities, combined with its artificial intelligence data analytics algorithms, to measure sleep, day time napping, overall daily activity levels and patterns using data collected from c.200 people at multiple time points. Furthermore, the study will allow the exploratory digital measures of patient quality of life to be evaluated alongside standard clinical measures.
Better measurement of day and night time sleep is of increasing interest in clinical research and clinical practice. For some diseases, it provides a measure of disease progression. Disrupted sleep or daytime somnolence could also represent a side effect of the medication. This could result in poor medication adherence or concerns around patient safety. Current methods of measuring sleep, daytime activity and somnolence typically rely on patient diaries or the use of rating scales. Continuous data collection using wearable biosensors has the potential to create more objective and real world measures of sleep and movement, in a specific context of use, as required by regulatory authorities.
This is IXICO's second commercial agreement involving wearable biosensors and follows on from a contract announced on 4 October 2017 to measure sleep disturbance from biosensor data collected from people with a neurological disorder.
Giulio Cerroni, CEO of IXICO, commented: "We are delighted to announce this first contract with a new biopharma customer, providing our wearable biosensor capabilities and technology to support this late phase clinical trial. This study is focused on monitoring the treatment of patients with a serious psychiatric disorder, further supporting our view that wearable biosensors have broad utility in clinical research in many therapeutic areas. These two contracts represent an excellent opportunity for IXICO to provide new, innovative digital technologies as part of our commercially led growth strategy."
For further information please contact:
IXICO plc Giulio Cerroni, Chief Executive Officer Susan Lowther, Chief Financial Officer |
Tel: +44 20 3763 7499 |
Shore Capital (Nomad and Broker) Edward Mansfield / Anita Ghanekar | Tel: +44 20 7408 4090 |
FTI Consulting Limited (Investor Relations) Simon Conway / Mo Noonan | Tel: +44 20 3727 1000 |
About IXICO
IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com